I agree with Hayward. Because even if something is written on the label, this will not prevent insurers and docs from prescribing off-label (as they currently do). In fact, I think nothing at all would change, other than a little label change.
That's the weird conundrum in this industry - there is not one, single entity causing infringement in most cases. It is simply a weakness in the "system". Unless docs were required by law to select an indication, then pharmacies have no idea what the script is for. And insurers can't prevent off-label script writing. And truthfully, if Hikma had simply labeled their PR materials correctly, then we wouldn't even have a case against THEM!
The system is really whacked.
So as I stated earlier, I'm not sure how this problem possibly gets resolved - even if we somehow win against Hikma.
Market Data 
Markets 
AI
